Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
NEW YORK , June 26, 2024 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the “Company”) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board of Directors has authorized
Oramed Letter to Shareholders
NEW YORK, June 26, 2024 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (“Oramed”) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. Dear Shareholders, In light of our recent announcement regarding Oramed’s $20 million stock repurchase program, we believe this is […]
